The role of the purinergic ligand-gated ion channel 7 receptor in common digestive system cancers.
Journal
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
ISSN: 1473-5709
Titre abrégé: Eur J Cancer Prev
Pays: England
ID NLM: 9300837
Informations de publication
Date de publication:
06 Nov 2023
06 Nov 2023
Historique:
medline:
9
11
2023
pubmed:
9
11
2023
entrez:
9
11
2023
Statut:
aheadofprint
Résumé
The incidence of digestive malignancies has increased in recent years, including colorectal cancer (CRC), hepatocellular carcinoma (HCC) and pancreatic cancer. Advanced stages of these cancers are prone to metastasis, which seriously reduce the standard of living of patients and lead to decline in the survival rate of patients. So far there are no good specific drugs to stop this phenomenon. It is very important and urgent to find new biomarkers and therapeutic targets. Purinergic ligand-gated ion channel 7 receptor (P2X7R) is ATP-gated and nonselective ion channel receptor involved in many inflammatory processes and cancer progression. P2X7R is present in many cancer cells and promotes or inhibits cancer development through signal transduction. Studies have presented that P2X7R plays a role in the proliferation and migration of digestive system cancers, such as CRC, HCC and pancreatic cancer. Therefore, P2X7R may serve as a biomarker or therapeutic target for digestive system cancers. This paper describes the structure and function of P2X7R, and mainly reviews the research progress on the role of P2X7R in CRC, HCC and pancreatic cancer.
Identifiants
pubmed: 37942897
doi: 10.1097/CEJ.0000000000000851
pii: 00008469-990000000-00101
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Adinolfi E, Raffaghello L, Giuliani AL, Cavazzini L, Capece M, Chiozzi P, et al. (2012). Expression of P2X7 receptor increases in vivo tumor growth. Cancer Res 72:2957–2969.
Adinolfi E, Capece M, Franceschini A, Falzoni S, Giuliani AL, Rotondo A, et al. (2015). Accelerated tumor progression in mice lacking the ATP receptor P2X7. Cancer Res 75:635–644.
de Andrade Mello P, Bian S, Savio LEB, hang H, Zhang J, Junger W, et al. (2017). Hyperthermia and associated changes in membrane fluidity potentiate P2X7 activation to promote tumor cell death. Oncotarget 8:67254–67268.
Anwanwan D, Singh SK, Singh S, Saikam V, Singh R (2020). Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer 1873:188314.
Arnaud-Sampaio VF, Rabelo ILA, Ulrich H, Lameu C (2020). The P2X7 receptor in the maintenance of cancer stem cells, chemoresistance and metastasis. Stem Cell Rev Rep 16:288–300.
Asif A, Khalid M, Manzoor S, Ahmad H, Rehman AU (2019). Role of purinergic receptors in hepatobiliary carcinoma in Pakistani population: an approach towards proinflammatory role of P2X4 and P2X7 receptors. Purinergic Signal 15:367–374.
Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D (2016). Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell 30:836–848.
Bernardazzi C, Castelo-Branco MTL, Pego B, Ribeiro BE, Rosas SLB, Santana PT, et al. (2022). The P2X7 receptor promotes colorectal inflammation and tumorigenesis by modulating gut microbiota and the inflammasome. Int J Mol Sci 23:4616.
Bian S, Sun X, Bai A, Zhang C, Li L, Enjyoji K, et al. (2013). P2X7 integrates PI3K/AKT and AMPK-PRAS40-mTOR signaling pathways to mediate tumor cell death. PLoS One 8:e60184.
Boldrini L, Giordano M, Alì G, Melfi F, Romano G, Lucchi M, et al. (2015). P2X7 mRNA expression in non-small cell lung cancer: MicroRNA regulation and prognostic value. Oncol Lett 9:449–453.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018). Global cancer statistics 2018 GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424.
Burnstock G (2020). Introduction to purinergic signalingpurinergic signaling. Methods Mol Biol 2041:1–15.
Cai S, Li Y, Ding Y, Chen K, Jin M (2014). Alcohol drinking and the risk of colorectal cancer death: a meta-analysis. Eur J Cancer Prev 23:532–539.
Calik I, Calik M, Turken G, Ozercan IH (2020). A promising independent prognostic biomarker in colorectal cancer: P2X7 receptor. Int J Clin Exp Pathol 13:107–121.
Cheewatrakoolpong B, Gilchrest H, Anthes JC, Greenfeder S (2005). Identification and characterization of splice variants of the human P2X7 ATP channel. Biochem Biophys Res Commun 332:17–27.
Choi JH, Ji YG, Ko JJ, Cho HJ, Lee DH (2018). Activating P2X7 receptors increases proliferation of human pancreatic cancer cells via ERK1/2 and JNK. Pancreas 47:643–651.
Coutinho-Silva R, Stahl L, Cheung KK, de Campos NE, de Oliveira Souza C, Ojcius DM, et al. (2005). P2X and P2Y purinergic receptors on human intestinal epithelial carcinoma cells: effects of extracellular nucleotides on apoptosis and cell proliferation. Am J Physiol Gastrointest Liver Physiol 288:G1024–G1035.
De Marchi E, Orioli E, Dal Ben D, Adinolfi E (2016). P2X7 receptor as a therapeutic target. Adv Protein Chem Struct Biol 104:39–79.
De Salis SKF, Li L, Chen Z, Lam KW, Skarratt KK, Balle T, et al. (2022). Alternatively spliced isoforms of the P2X7 receptor: structure, function and disease associations. Int J Mol Sci 23:8174.
Di Virgilio F, Adinolfi E (2017a). Extracellular purines, purinergic receptors and tumor growth. Oncogene 36:293–303.
Di Virgilio F, Chiozzi P, Ferrari D, Falzoni S, Sanz JM, Morelli A, et al. (2001). Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood 97:587–600.
Di Virgilio F, Dal Ben D, Sarti AC, Giuliani AL, Falzoni S (2017b). The P2X7 Receptor in Infection and Inflammation. Immunity 47:15–31.
Di Virgilio F, Sarti AC, Falzoni S, De Marchi E, Adinolfi E (2018a). Extracellular ATP and P2 purinergic signalling in the tumour microenvironment. Nat Rev Cancer 18:601–618.
Di Virgilio F, Schmalzing G, Markwardt F (2018b). The elusive P2X7 macropore. Trends Cell Biol 28:392–404.
Di Virgilio F, Jiang L-H, Roger S, Falzoni S, Sarti AC, Vultaggio-Poma V, et al. (2019). Structure, function and techniques of investigation of the P2X7 receptor (P2X7R) in mammalian cells. Methods Enzymol 629:115–150.
Duan S, Yu J, Han Z, Cheng Z, Liang P (2016). Association between P2RX7 gene and hepatocellular carcinoma susceptibility: a case-control study in a Chinese Han Population. Med Sci Monit 22:1916–1923.
Feng YH, Li X, Wang L, Zhou L, Gorodeski GI (2006). A truncated P2X7 receptor variant (P2X7-j) endogenously expressed in cervical cancer cells antagonizes the full-length P2X7 receptor through hetero-oligomerization. J Biol Chem 281:17228–17237.
Gartland A, Hipskind RA, Gallagher JA, Bowler WB (2001). Expression of a P2X7 receptor by a subpopulation of human osteoblasts. J Bone Miner Res 16:846–856.
Ghalali A, Martin-Renedo J, Hogberg J, Stenius U (2017). Atorvastatin decreases HBx-induced Phospho-Akt in hepatocytes via P2X receptors. Mol Cancer Res 15:714–722.
Giannuzzo A, Pedersen SF, Novak I (2015). The P2X7 receptor regulates cell survival, migration and invasion of pancreatic ductal adenocarcinoma cells. Mol Cancer 14:203.
Giannuzzo A, Saccomano M, Napp J, Ellegaard M, Alves F, Novak I (2016). Targeting of the P2X7 receptor in pancreatic cancer and stellate cells. Int J Cancer 139:2540–2552.
Gilbert SM, Gidley Baird A, Glazer S, Barden JA, Glazer A, Teh LC, et al. (2017). A phase I clinical trial demonstrates that nfP2X7 -targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma. Br J Dermatol 177:117–124.
Gilbert SM, Oliphant CJ, Hassan S, Peille AL, Bronsert P, Falzoni S, et al. (2019). ATP in the tumour microenvironment drives expression of nfP2X7, a key mediator of cancer cell survival. Oncogene 38:194–208.
Goral V (2015). Pancreatic cancer: pathogenesis and diagnosis. Asian Pac J Cancer Prev 16:5619–5624.
Guo J, Yang P, Li YF, Tang JF, He ZX, Yu SG, et al. (2023). MicroRNA: Crucial modulator in purinergic signalling involved diseases. Purinergic Signal 19:329–341.
Haanes KA, Schwab A, Novak I (2012). The P2X7 receptor supports both life and death in fibrogenic pancreatic stellate cells. PLoS One 7:e51164.
He L, Hannon GJ (2004). MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5:522–531.
Hofman P, Cherfils-Vicini J, Bazin M, Ilie M, Juhel T, Hebuterne X, et al. (2015). Genetic and pharmacological inactivation of the purinergic P2RX7 receptor dampens inflammation but increases tumor incidence in a mouse model of colitis-associated cancer. Cancer Res 75:835–845.
Horauf JA, Kany S, Janicova A, Xu B, Vrdoljak T, Sturm R, et al. (2020). Short Exposure to ethanol diminishes caspase-1 and ASC activation in human HepG2 cells in vitro. Int J Mol Sci 21:3196.
Huang S, Chen Y, Wu W, Ouyang N, Chen J, Li H, et al. (2013). miR-150 promotes human breast cancer growth and malignant behavior by targeting the pro-apoptotic purinergic P2X7 receptor. PLoS One 8:e80707.
Ilic M, Ilic I (2016). Epidemiology of pancreatic cancer. World J Gastroenterol 22:9694–9705.
Kaczmarek-Hájek K, Lörinczi E, Hausmann R, Nicke A (2012). Molecular and functional properties of P2X receptors--recent progress and persisting challenges. Purinergic Signal 8:375–417.
Kennedy C (2021a). That was then, this is now: the development of our knowledge and understanding of P2 receptor subtypes. Purinergic Signal 17:9–23.
Kennedy C (2021b). The P2Y/P2X divide: how it began. Biochem Pharmacol 187:114408.
Keum N, Bao Y, Smith-Warner SA, Orav J, Wu K, Fuchs CS, et al. (2016). Association of physical activity by type and intensity with digestive system cancer risk. JAMA Oncol 2:1146–1153.
Khalid M, Manzoor S, Ahmad H, Asif A, Bangash TA, Latif A, et al. (2018). Purinoceptor expression in hepatocellular virus (HCV)-induced and non-HCV hepatocellular carcinoma: an insight into the proviral role of the P2X4 receptor. Mol Biol Rep 45:2625–2630.
Kunzli BM, Berberat PO, Giese T, Csizmadia E, Kaczmarek E, Baker C, et al. (2007). Upregulation of CD39/NTPDases and P2 receptors in human pancreatic disease. Am J Physiol Gastrointest Liver Physiol 292:G223–G230.
Lenertz LY, Gavala ML, Zhu Y, Bertics PJ (2011). Transcriptional control mechanisms associated with the nucleotide receptor P2X7, a critical regulator of immunologic, osteogenic, and neurologic functions. Immunol Res 50:22–38.
Li Q, Zhu X, Song W, Peng X, Zhao R (2020). The P2X7 purinergic receptor: a potential therapeutic target for lung cancer. J Cancer Res Clin Oncol 146:2731–2741.
Lin QJ, Yang F, Jin C, Fu DL (2015). Current status and progress of pancreatic cancer in China. World J Gastroenterol 21:7988–8003.
Liu H, Liu W, Liu Z, Liu Y, Zhang W, Xu L, et al. (2015). Prognostic value of purinergic P2X7 receptor expression in patients with hepatocellular carcinoma after curative resection. Tumour Biol 36:5039–5049.
Magni L, Bouazzi R, Heredero Olmedilla H, Petersen PSS, Tozzi M, Novak I (2021). The P2X7 receptor stimulates IL-6 release from pancreatic stellate cells and tocilizumab prevents activation of STAT3 in pancreatic cancer cells. Cells 10:1928.
Marengo A, Rosso C, Bugianesi E (2016). Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med 67:103–117.
Martinez-Cuesta MA, Blanch-Ruiz MA, Ortega-Luna R, Sanchez-Lopez A, Alvarez A (2020). Structural and functional basis for understanding the biological significance of P2X7 receptor. Int J Mol Sci 21:8454.
McCarthy AE, Yoshioka C, Mansoor SE (2019). Full-length P2X7 structures reveal how palmitoylation prevents channel desensitization. Cell 179:659–670.e13.
McGlynn KA, Petrick JL, London WT (2015). Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis 19:223–238.
Mehta N, Kaur M, Singh M, Chand S, Vyas B, Silakari P, et al. (2014). Purinergic receptor P2X(7): a novel target for anti-inflammatory therapy. Bioorg Med Chem 22:54–88.
Mistafa O, Stenius U (2009). Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells. Biochem Pharmacol 78:1115–1126.
Mohammed A, Qian L, Janakiram NB, Lightfoot S, Steele VE, Rao CV (2012). Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice. Int J Cancer 131:1951–1962.
Mohammed A, Janakiram NB, Madka V, Pathuri G, Li Q, Ritchie R, et al. (2017). Lack of chemopreventive effects of P2X7R inhibitors against pancreatic cancer. Oncotarget 8:97822–97834.
Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al.; WHO Classification of Tumours Editorial Board (2020). The 2019 WHO classification of tumours of the digestive system. Histopathology 76:182–188.
Ni J, Zhang Z, Luo X, Xiao L, Wang N (2016). Plasticizer DBP activates NLRP3 inflammasome through the P2X7 receptor in HepG2 and L02 Cells. J Biochem Mol Toxicol 30:178–185.
van Niel G, D’Angelo G, Raposo G (2018). Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol 19:213–228.
Novak I, Yu H, Magni L, Deshar G (2020). Purinergic signaling in pancreas-from physiology to therapeutic strategies in pancreatic cancer. Int J Mol Sci 21:8781.
Orcutt ST, Anaya DA (2018). Liver resection and surgical strategies for management of primary liver cancer. Cancer Control 25:1073274817744621.
Pegoraro A, De Marchi E, Ferracin M, Orioli E, Zanoni M, Bassi C, et al. (2021). P2X7 promotes metastatic spreading and triggers release of miRNA-containing exosomes and microvesicles from melanoma cells. Cell Death Dis 12:1088.
Qian F, Xiao J, Hu B, Sun N, Yin W, Zhu J (2017). High expression of P2X7R is an independent postoperative indicator of poor prognosis in colorectal cancer. Hum Pathol 64:61–68.
Qiu Y, Li WH, Zhang HQ, Liu Y, Tian XX, Fang WG (2014). P2X7 mediates ATP-driven invasiveness in prostate cancer cells. PLoS One 9:e114371.
Rotondo JC, Mazziotta C, Lanzillotti C, Stefani C, Badiale G, Campione G, et al. (2022). The role of purinergic P2X7 receptor in inflammation and cancer: novel molecular insights and clinical applications. Cancers (Basel) 14:1116.
Saha M, Manna K, Das Saha K (2022). Melatonin suppresses NLRP3 inflammasome activation via TLR4/NF-kappaB and P2X7R signaling in high-fat diet-induced murine NASH model. J Inflamm Res 15:3235–3258.
Sainz B Jr, Alcala S, Garcia E, Sanchez-Ripoll Y, Azevedo MM, Cioffi M, et al. (2015). Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. Gut 64:1921–1935.
Savio LEB, de Andrade Mello P, da Silva CG, Coutinho-Silva R (2018). The P2X7 receptor in inflammatory diseases: angel or demon? Front Pharmacol 9:52.
Shalapour S, Karin M (2020). Cruel to be kind: epithelial, microbial, and immune cell interactions in gastrointestinal cancers. Annu Rev Immunol 38:649–671.
Sluyter R (2017). The P2X7 receptor. Adv Exp Med Biol 1051:17–53.
Sluyter R, Stokes L (2011). Significance of P2X7 receptor variants to human health and disease. Recent Pat DNA Gene Seq 5:41–54.
Solini A, Cuccato S, Ferrari D, Santini E, Gulinelli S, Callegari MG, et al. (2008). Increased P2X7 receptor expression and function in thyroid papillary cancer: a new potential marker of the disease? Endocrinology 149:389–396.
Solini A, Cobuccio L, Rossi C, Parolini F, Biancalana E, Cosio S, et al. (2022). Molecular characterization of peritoneal involvement in primary colon and ovary neoplasm: the possible clinical meaning of the P2X7 receptor-inflammasome complex. Eur Surg Res 63:114–122.
Souza CO, Santoro GF, Figliuolo VR, Nanini HF, de Souza HS, Castelo-Branco MTL, et al. (2012). Extracellular ATP induces cell death in human intestinal epithelial cells. Biochim Biophys Acta 1820:1867–1878.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. (2021). Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249.
Surprenant A, Rassendren F, Kawashima E, North RA, Buell G (1996). The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 272:735–738.
Tan C, Han LI, Zou L, Luo C, Liu A, Sheng X, et al. (2015). Expression of P2X7R in breast cancer tissue and the induction of apoptosis by the gene-specific shRNA in MCF-7 cells. Exp Ther Med 10:1472–1478.
Taylor JM, Han Z (2010). Purinergic receptor functionality is necessary for infection of human hepatocytes by hepatitis delta virus and hepatitis B virus. PLoS One 5:e15784.
Thanikachalam K, Khan G (2019). Colorectal cancer and nutrition. Nutrients 11:164.
Wang J, Cheng M, Law IKM, Ortiz C, Sun M, Koon HW (2019). Cathelicidin suppresses colon cancer metastasis via a P2RX7-dependent mechanism. Mol Ther Oncolytics 12:195–203.
Wang HY, Wang YP, Zeng X, Zheng Y, Guo QH, Ji R, et al. (2020). Circular RNA is a popular molecule in tumors of the digestive system (Review). Int J Oncol 57:21–42.
Wiley JS, Sluyter R, Gu BJ, Stokes L, Fuller SJ (2011). The human P2X7 receptor and its role in innate immunity. Tissue Antigens 78:321–332.
Wu Y, Yang S, Ma J, Chen Z, Song G, Rao D, et al. (2022). Spatiotemporal immune landscape of colorectal cancer liver metastasis at single-cell level. Cancer Discov 12:134–153.
Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. (2022). Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl) 135:584–590.
Yang C, Shi S, Su Y, Tong JS, Li L (2020). P2X7R promotes angiogenesis and tumour-associated macrophage recruitment by regulating the NF-kappaB signalling pathway in colorectal cancer cells. J Cell Mol Med 24:10830–10841.
Young CNJ, Gorecki DC (2018). P2RX7 Purinoceptor as a therapeutic target-the second coming? Front Chem 6:248.
Zhang Y, Li F, Wang L, Lou Y (2012). A438079 affects colorectal cancer cell proliferation, migration, apoptosis, and pyroptosis by inhibiting the P2X7 receptor. Biochem Biophys Res Commun 558:147–153.
Zhang Y, Jin Q, Li X, Jiang M, Cui BW, Xia KL, et al. (2018). Amelioration of alcoholic liver steatosis by dihydroquercetin through the modulation of AMPK-dependent lipogenesis mediated by P2X7R-NLRP3-inflammasome activation. J Agric Food Chem 66:4862–4871.
Zhang Y, Ding J, Wang L (2019). The role of P2X7 receptor in prognosis and metastasis of colorectal cancer. Adv Med Sci 64:388–394.
Zhang WJ, Hu CG, Zhu ZM, Luo HL (2020). Effect of P2X7 receptor on tumorigenesis and its pharmacological properties. Biomed Pharmacother 25:109844.
Zhang WJ, Luo C, Huang C, Pu FQ, Zhu JF, Zhu ZM (2021). PI3K/Akt/GSK-3beta signal pathway is involved in P2X7 receptor-induced proliferation and EMT of colorectal cancer cells. Eur J Pharmacol 899:174041.
Zhao Z, Liu W (2020). Pancreatic cancer: a review of risk factors, diagnosis, and treatment. Technol Cancer Res Treat 19:1533033820962117.
Zhou L, Qi X, Potashkin J A, Abdul-Karim F W, Gorodeski GI (2008). MicroRNAs miR-186 and miR-150 down-regulate expression of the pro-apoptotic purinergic P2X7 receptor by activation of instability sites at the 3’-untranslated region of the gene that decrease steady-state levels of the transcript. J Biol Chem 283:28274–28286.
Zhu X, Li Q, Song W, Peng X, Zhao R (2021). P2X7 receptor: a critical regulator and potential target for breast cancer. J Mol Med (Berl) 99:349–358.
Ziberi S, Zuccarini M, Carluccio M, Giuliani P, Ricci-Vitiani L, Pallini R, et al. (2019). Upregulation of epithelial-to-mesenchymal transition markers and P2X7 receptors is associated to increased invasiveness caused by P2X7 receptor stimulation in human glioblastoma stem cells. Cells 9:85.